Author:
Zorn Kristin K.,Gardner Ginger J.,Birrer Michael J.
Reference208 articles.
1. NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 1995;273:491–497.
2. Selvakumaran M, Bao R, Crijns AP, et al. Ovarian epithelial cell lineage-specific gene expression using the promoter of a retrovirus-like element. Cancer Res 2001;61:1291–1295.
3. Levy-Lahad E, Krieger M, Gottfeld O, et al. BRCA1 and BRCA2 mutation carriers as potential candidates for chemoprevention trials. J Cell Biochem Suppl 2000;34:13–18.
4. Rodriguez-Burford C, Barnes MN, Berry W, et al. Immunohistochemical expression of molecular markers in an avian model: a potential model for preclinical evaluation of agents for ovarian cancer chemoprevention. Gynecol Oncol 2001;81:373–379.
5. Brewer MA, Mitchell MF, Bast RC. Prevention of ovarian cancer. In Vivo 1999;13:99–106.